Clinical stage specialty pharmaceutical company Vascarta Inc announced on Monday that it has obtained the exclusive rights to a novel method of creating more effective cancer therapies with fewer side effects by implementing new and unique linker chemistry developed by the City College of New York (CUNY).
CUNY's novel, patent-pending technology licensed by Vascarta involves linking proven anti-cancer therapeutics such as paclitaxel (Taxol), gemcitabine (Gemzar), doxorubicin (Adriamycin), and methotrexate (Jylamvo) with curcumin. Linking the anti-cancer agents to curcumin optimises the effectiveness of both agents. The linker was designed to undergo breakage once the compound enters a cell.
Dr. Probal Banerjee (inventor of the linker chemistry and professor of Chemistry, Biochemistry, and Neuroscience at CUNY) said: "These new linked molecules are showing greatly increased anti-cancer efficacy, offering the possibility for a new cancer treatment paradigm."
Dr. Joel Friedman, professor, Department of Microbiology & Immunology, Albert Einstein College of Medicine, and scientific founder & chief scientific officer of Vascarta, added: "Linked curcumin-chemotherapeutic compounds enhances curcumin's bioavailability facilitating more convenient, non-parenteral administration in patients as well as reducing unwanted side effects."
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Invenra and Orion partner to develop bispecific antibody cancer therapies
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
Diatech Pharmacogenetics expands Merck collaboration for colorectal cancer testing